Literature DB >> 11792680

UDP glucuronosyltransferase mRNA levels in human liver disease.

Mario Congiu1, Maurice L Mashford, John L Slavin, Paul V Desmond.   

Abstract

The UDP glucuronosyltransferases (UGT) are a family of enzymes in which substrates include drugs, xenobiotics, and products of endogenous catabolism. The main source of most UGT enzymes is the liver, a major organ in the detoxification and inactivation of compounds. Previous studies have indicated that glucuronidation, as measured by pharmacokinetic studies, is relatively spared in liver disease. Because UGT activity toward most substrates is the result of metabolism by different isoforms with overlapping specificities, these studies may not indicate the effect of disease on the levels of individual isoforms. We sought to extend these studies to the measurement of mRNA for individual isoforms in the liver of patients with various forms of liver disease. RNA was extracted from liver tissue samples of patients undergoing clinically necessary percutaneous liver biopsies. UGT mRNA levels for isoforms 1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B10, 2B11, 2B15, and 2B17 were determined by real-time reverse transcription-polymerase chain reaction. Biopsies were graded using the Metavir system. Results from patients with low fibrosis or inflammatory scores were compared with those with high scores. We found large interindividual variation in the levels of the various isoforms. This was greatest for UGT2B17. A consistent downward trend, reaching statistical significance for UGT1A4, UGT2B4, and UGT2B7, was observed in samples from patients with high inflammation scores. There was no such correlation with the degree of fibrosis. Our results indicate that hepatic UGT mRNA levels are reduced while the tissue is inflamed, but they are not affected in the noninflamed, chronically diseased liver.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792680     DOI: 10.1124/dmd.30.2.129

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

Review 4.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.

Authors:  Célia Lloret-Linares; Déborah Hirt; Christophe Bardin; Jean-Luc Bouillot; Jean-Michel Oppert; Christine Poitou; François Chast; Stéphane Mouly; Jean-Michel Scherrmann; Jean-François Bergmann; Xavier Declèves
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

6.  Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Authors:  Sabrina Jones; Azure L Yarbrough; Amal Shoeib; John M Bush; William E Fantegrossi; Paul L Prather; Anna Radominska-Pandya; Ryoichi Fujiwara
Journal:  Xenobiotica       Date:  2019-03-20       Impact factor: 1.908

7.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

8.  Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

Authors:  Dione Gardner-Stephen; Jean-Marie Heydel; Amit Goyal; Yuan Lu; Wen Xie; Tim Lindblom; Peter Mackenzie; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

Review 9.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

10.  Glycan-related gene expression signatures in human metastatic hepatocellular carcinoma cells.

Authors:  Xiaonan Kang; Nian Wang; Chen Pei; Lu Sun; Ruixia Sun; Jie Chen; Yinkun Liu
Journal:  Exp Ther Med       Date:  2011-12-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.